Journal of Clinical Pharmacology

Article	Citations
Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows	74
Pharmacokinetics and Safety of a Novel Extended‐Release Microsphere Formulation of Risperidone in Patients with Schizophrenia or Schizoaffective Disorder	52
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real‐World Data: A Pharmacokinetic–Pharmacodynamic Modeling Approach	48
Vancomycin Associated Purpuric Symmetrical Drug‐Related Intertriginous and Flexural Exanthema: A Rare Association and an Uncommon Presentation	46
Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia	43
	36
Development and Verification of a Japanese Pediatric Physiologically Based Pharmacokinetic Model with Emphasis on Drugs Eliminated by Cytochrome P450 or Renal Excretion	29
Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care	29
	26
Protecting Mothers and Babies Through Research	25
Thyroid Antibody Titers and Hypothalamic‐Pituitary‐Thyroid Axis Activity in Levothyroxine‐Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin	24
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides	23
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A	23
Exploring Factors Affecting the Occurrence of Hypersensitivity Reactions Induced by Nonionic Iodine Contrast Media	22
Maternal–Fetal Drug Development: An Industry Perspective	22
	22
Association Between the Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Drug‐Induced Acute Kidney Injury: Analysis of 2 Databases	21
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations	20
What Is the Role of Sex‐Related Differences in the Effectiveness and Safety of Biological Drugs Used in Patients With Severe Asthma?	19
Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study	18
Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab	18
Challenges in Conducting Therapeutic Trials in Pregnancy: Emphasizing Recent Lessons Learned	17
Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework	16
Issue Information	16
The Role of the Mesencephalic Astrocyte‐Derived Neurotrophic Factor in Patients in Intensive Care Units Receiving Voriconazole Therapy	16

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates	16
Issue Information	16
Issue Information	16
Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	16
Issue Information	16
A Phase I Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Liposomal Bupivacaine for Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy	15
Comparison of Misoprostol and Evening Primrose Oil on Cervical Preparation Before Gynecological Surgery	15
Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment	15
Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses	14
Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders	14
Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame	14
Influence of Prednisone on Inflammatory Biomarkers in Community‐Acquired Pneumonia: Secondary Analysis of a Randomized Trial	14
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib	14
Issue Information	13
Risk Factors for Angiotension‐Converting Enzyme Inhibitor–Associated Cough	13
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity	13
Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer	13
Contemporary Use of Oral Inotropes in the Outpatient Treatment of Heart Failure: Analysis of a Japanese Nationwide Database	13
Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance	13
Using Real‐World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants	13
Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01‐0371) in Adult Patients with Pulmonary Tuberculosis	13
Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation	13
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration	13
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials	13
Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation	12
Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction	12
Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients	12
Will the Pharmacologically Meaningful Half‐Life Please Stand Up?	12
Characterization of Immune Checkpoint Inhibitor–Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System	12
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors	12
An Investigation in the Comparability of the Exposure and Recommended Dose of Selected Pfizer Drugs in East Asian Countries: Is Mutual Usage of Clinical Data Among East Asian Countries Feasible?	12
Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 Diabetes	12
Efficacy of Bile Acid Sequestrants in the Treatment of Bile Acid Diarrhea: A Meta‐Analysis of Randomized Controlled Trials	12
	11
In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor	11
Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023	11
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy	11
Comparison of Two Dexmedetomidine Administration Strategies on the Incidence of Postoperative Respiratory Complications: A Retrospective, Inverse Probability of Treatment Weighted Study	10
Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors	10
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists	10
Clinical Consequences of Altered Drug Disposition in Obesity: Call for Change	10
	10
A Retrospective Cohort Study Examining the Effects of Anti‐PD‐1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2‐Negative Advanced Gastric/Gastroesophageal Junction Cancer	10
Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies	10
Risk of Pregabalin‐Induced Hypoglycemia: Analysis of the Japanese Adverse Drug Event Report Database	10
Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation	10
Understanding and Streamlining Dose Finding: From Dose Simulation to Dose Estimation	10
Issue Information	10
Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM	9
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis	9

Correction to “The Association Between Concurrence of Infection and the Onset of Severe Eruption or Liver Injury in Patients Using Antipyretic Analgesics: A Matched, Nested Case‐Control Study”	9
In Silico Modeling for Ex Vivo Placental Transfer of Morphine	9
Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling	9
Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations	9
Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis	9
Regulatory Framework for Drug Development in Rare Diseases	9
Back Pedaling on Baclofen: Highlighting Concerns Surrounding Baclofen use in Phenibut Withdrawal	9
Exposure–Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia	9
Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors	9
Capillary Filtration of Plasma is Accelerated During General Anesthesia: A Secondary Population Volume Kinetic Analysis	8
JCP 2022 Reviewer Thank‐You List	8
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID‐19) in India	8
Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	8
Expansion of a Pharmacokinetic Model for Diazepam to Characterize Real‐World IV and Oral Data in Children With and Without Obesity	8
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy	8
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus	8
Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on	8
Preclinical and Clinical Pharmacokinetics of JNJ‐75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction‐Associated Steatohepatitis	8
2023 JCP Peer Reviewer List	8
	8
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia	8
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation	8
Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut‐Point Suitability Across Tumor Types	8
Issue Information	8
Preventing a New Tuskegee: Food and Drug Administration Oversight of Overseas Research Must Match That in the United States	8
Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies	8
Risk of SARS‐CoV‐2 Infection and COVID‐19 Severity Associated With Exposure to Nonsteroidal Anti‐Inflammatory Drugs: Systematic Review and Meta‐Analysis	8
Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder	8
	7
	7
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide	7
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware	7
A Target‐Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI‐62 in Healthy Adults	7
Evaluation of Preoperative Risk Factors for Sugammadex‐Induced Anaphylaxis: Analysis of the Japanese Adverse Drug Event Report Database	7
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants	7
Reply to: Comment: Cerebrospinal Fluid Pharmacokinetics of Nicardipine Following Intrathecal Administration in Subarachnoid Hemorrhage Patients	7
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis	7
Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities	7
Over‐the‐Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit	7
Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma	7
Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide–Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma	7
Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture	7
	7
Correction	7
Efficacy and Safety of Adjunctive Serotonin‐Dopamine Activity Modulators in Major Depression: A Meta‐Analysis of Randomized Controlled Trials	7
Physiologically Based Pharmacokinetic Modeling of Vancomycin in Critically Ill Neonates: Assessing the Impact of Pathophysiological Changes	7
Once‐ Versus Twice‐Daily Tacrolimus Therapy: Does Improved Adherence Lead to Better Efficacy?—A Pharmacokinetic Perspective	7
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia	7
Issue Information	7
Evaluation of the Efficacy of Dexmedetomidine as a Local Anesthetic Adjuvant in Children: A Meta‐Analysis of Randomized Controlled Trials	7
Myelosuppression Caused by Nanoparticle Albumin‐Bound Paclitaxel in the Northern Chinese Population and the Role of Body Composition	7
Missed Opportunities: Intravenous versus Oral Antibiotic De‐escalation for Treatment of Lower Extremity Osteoarticular Infections	7
Pharmacogenomics for Drug Dosing in Children: Current Use, Knowledge, and Gaps	7
Street Pharmacology: Toxico‐Dermatology of Injection Drug Use	7
Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data	6
Issue Information	6
Population Pharmacokinetic Analysis of N‐Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant	6
Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study	6
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation	6
Issue Information	6
Study of the Association of Single Nucleotide Polymorphisms in Candidate Genes With Sevoflurane	6
Issue Information	6
Issue Information	6
In Memoriam: Varsha Bhatt‐Mehta, PharmD, MS, FCCP	6
In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation	6
Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products	6
	6
Issue Information	6
Issue Information	6
Gastrointestinal Bleeding During Direct Oral Anticoagulant Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of Polypharmacy	6
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease	6
Genetic Polymorphism as a Possible Cause of Severe Postoperative Pain	6
Changing Trajectories of Alanine Aminotransferase and Risk of Antituberculosis Drug‐Induced Liver Injury in Chinese Patients: A Cohort Study	6
US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information	6
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist	6
Evaluation of Cannabis Per Se Laws: A Semi‐Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users	5
Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study	5
Modification of Vancomycin Dosing in Cardiac Surgery With Cardiopulmonary Bypass	5
Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia	5
Clinical Pharmacokinetics From the Beginning: A Practical Approach	5

Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis	5
Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling	5
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis	5
Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry	5
Issue Information	5
	5
Conflation of Tuskegee Study With FDA Fiduciary Responsibilities Sensationally Ignores International Law	5
Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects	5
Comparison of Clinical Effectiveness Between Ambroxol and N‐Acetylcysteine in Surgical Patients: A Retrospective Cohort Study	5
Limited Sampling Strategy for Predicting the Area under Plasma Concentration–Time Curve of Nadolol in Healthy Subjects	5
Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development	5
Vaginal Misoprostol Pharmacokinetic Changes in Obese Parturient Women Who Presented Labor Induction Failure	5
Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity	5
Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome	5
	5
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes	5
Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?	4
The Role of Pain Medications in Modulating Peripheral Nerve Injury Recovery	4
Evaluation of Drug‐Drug Interactions of Ensitrelvir, a SARS‐CoV‐2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies	4
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma	4
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study	4
Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring	4
Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin	4
ACCP Position Statement on Unregulated Psychotropic Products	4
Infant Dextromethorphan and Dextrorphan Exposure via Breast Milk From Mothers Who Are CYP2D6 Extensive Metabolizers	4
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta‐Analysis	4
Baricitinib: From Rheumatoid Arthritis to COVID‐19	4
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs	4
Response to Letter to the Editor From Dr. Cimolai	4
A Retrospective Analysis of Intravenous vs Oral Antibiotic Step‐Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections	4
The Impact of Survival Benefit and Study Design on FDA Approval for Anticancer Drugs Over the Past Decades	4
Drug Combination Modeling: Methods and Applications in Drug Development	4
Relationship Between Apparent Systemic Clearance of Vemurafenib and Toxicity in Patients With Melanoma	4
In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers	4
Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure	4
Use of Propensity Scoring and Its Application to Real‐World Data: Advantages, Disadvantages, and Methodological Objectives Explained to Researchers Without Using Mathematical Equations	4
Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes	4
Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients	4
Issue Information	4
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia	4
Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach	4
Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function	4
	4
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response	4
Model‐Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children	4
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis	4
A Retrospective Analysis of PK and Response of Oral Ibuprofen in the Treatment of a Patent Ductus Arteriosus in Extremely Low Gestational Age Neonates	4
Novel Patient‐Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use	4
Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti‐Tuberculosis Drug‐Induced Liver Injury	4
Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis	4
ChatGPT and Factual Knowledge Questions Regarding Clinical Pharmacy: Response to Letter to the Editor	4
Obesity Considerations in Pediatric Drug Development, 2016–2021	4
Neurological Immune‐Related Adverse Events After COVID‐19 Vaccination: A Systematic Review	4
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (	4
Population Pharmacokinetics of Caffeine in Infants with Hypoxic‐Ischemic Encephalopathy: A Phase I, Dose‐Escalating Trial	4
Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K	4
Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial	4
Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia	4